Is testosterone therapy safe and appropriate for menopausal women, given it isn't FDA-approved for them?

This is a genuine, live disagreement in the evidence. Both sides below are independently sourced and graded — read the grades, not just the labels.

Evidence-based benefit for a specific, well-defined use

Physiological-dose testosterone therapy has strong, multi-society-endorsed evidence for treating hypoactive sexual desire disorder specifically — improving satisfying sexual events and reducing sexual distress in postmenopausal women. Evidence does not support using it for energy, mood, or general well-being, and prescribing outside the HSDD indication isn't well supported.

AStrong evidence

Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.

No FDA-approved product, and real long-term safety gaps

No testosterone product is FDA-approved for women in the U.S., forcing off-label or compounded use with inconsistent dosing. Long-term cardiovascular and breast-cancer safety data genuinely don't exist for this use, and pellet formulations specifically carry documented dosing and safety concerns that clinical bodies have warned against.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.